Navigation Links
DuPont Group Vice President Briefs Investors on Performance Materials Segment
Date:12/5/2007

NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- At a briefing today with security analysts, Diane H. Gulyas, group vice president -- DuPont Performance Materials, discussed the segment's growth and productivity strategies. With more than $6 billion in annual sales, the DuPont Performance Materials platform is delivering customer-driven product innovation and value-added applications development for the global packaging, transportation, electrical and construction markets.

"We have delivered strong revenue and earnings growth by introducing innovative new products and end-use applications, while driving cost productivity," Gulyas said. "Our product innovations have supported price gains and our cost focus has been especially important in light of the significant increase in raw material costs over the past three years. We also have increased our global presence with strong growth in emerging markets.

"We see exciting new growth opportunities that we will pursue by leveraging DuPont polymer, nanotechnology and biotechnology science in photovoltaics, advanced metals replacement and renewable polymers. At the same time, we will continue to deliver valuable, high-performance polymer materials and solutions to our customers at attractive returns on capital," Gulyas said.

Today's presentation can be found at the Investor Center of the company's website at http://www.dupont.com.

DuPont (NYSE: DD) is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in DuPont's filings with the Securities and Exchange Commission, particularly its latest annual report on Form 10-K, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions of countries in which the company does business; competitive pressures; successful integration of structural changes, including acquisitions, divestitures and alliances; research and development of new products, including regulatory approval and market acceptance, and seasonality of sales of agricultural products.


'/>"/>
SOURCE DuPont
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DuPont Focused on Meeting Global Demands for Greater Safety & Protection
2. DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
3. DuPont Scores a Hat Trick for Innovation
4. DuPont Responds to Spelter, W.Va., Lawsuit Decision
5. Broad-based group of physicians calls for improvement in stroke treatment
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. CIGNA Group Insurance Shows Consumers Theres More to Life Through a New Consumer Education Toolkit
8. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. UTC Power Acquires Dome-Tech Group
11. Sutter Health Medical Groups Among the Best for Health Care Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: